A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors With Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma

Trial Profile

A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors With Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Anal cancer; HIV-1 infections; Hodgkin's disease; Kaposi's sarcoma; Lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jun 2018 As of 2 Feb 2018, 29 pts have been enrolled, according to trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 19 Jul 2017 Addition of cohort a Cohort of HIV-Associated Classical Hodgkin Lymphoma to the traial,hence change in patient number from42 to84.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top